Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Pharm ; 403(1-2): 276-84, 2011 Jan 17.
Artículo en Inglés | MEDLINE | ID: mdl-21044878

RESUMEN

The main objective of this study was to prepare two types of nanoparticles with poly(d,l-lactide-co-glycolide) (PLGA) and polyethylenimine (PEI) polymers. Plasmid DNA (pDNA) was adsorbed either on PLGA/PEI nanoparticles, or as PEI/DNA complex onto the surface of PLGA nanoparticles. Both types of nanoparticles were prepared by the double emulsion method. The nanoparticles were characterized by their size, zeta potential and pDNA or PEI/DNA complex adsorption. The PEI/DNA complex adsorption was confirmed with ethidium bromide assay. pDNA adsorption onto PLGA/PEI nanoparticles (PLGA/PEI-DNA) was studied by electrophoresis on agarose gel. Cytotoxicity and transfection efficiency of both types of nanoparticle and PEI/DNA complexes formulations were studied in head and neck squamous carcinoma cell line (FaDu). To improve endosomal release, photochemical internalization (PCI) was used. The zeta potential increased when the PEI/DNA complex adsorbed onto PLGA nanoparticles (PLGA-PEI/DNA). Optimal pDNA adsorption efficiency was achieved for nitrogen/phosphorous ratio≥20/1. In vitro transfection and cells viability on FaDu cells with or without PCI were found to be variable depending on the type and concentration of nanoparticles. The results showed that transfection efficiency for PLGA/PEI-DNA or PLGA-PEI/DNA nanoparticles ranged between 2 and 80%, respectively. PCI was found to slightly improve the transfection efficiency for all formulations.


Asunto(s)
ADN , Portadores de Fármacos/química , Iminas/química , Ácido Láctico/química , Nanopartículas/química , Plásmidos , Polietilenos/química , Ácido Poliglicólico/química , Transfección , Adsorción , Técnicas de Cultivo de Célula , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , ADN/administración & dosificación , ADN/genética , ADN/efectos de la radiación , Electroforesis en Gel de Agar , Escherichia coli/genética , Proteínas Fluorescentes Verdes/genética , Humanos , Tamaño de la Partícula , Procesos Fotoquímicos , Fármacos Fotosensibilizantes/farmacología , Plásmidos/administración & dosificación , Plásmidos/genética , Plásmidos/efectos de la radiación , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Porfirinas/farmacología
2.
Int J Pharm ; 314(2): 127-36, 2006 May 18.
Artículo en Inglés | MEDLINE | ID: mdl-16490330

RESUMEN

The aim of this study was to prepare different types of paclitaxel-loaded, PLGA-based microparticles and lipidic implants, which can directly be injected into the brain tissue. Releasing the drug in a time-controlled manner over several weeks, these systems are intended to optimize the treatment of brain tumors. The latter is particularly difficult because of the blood-brain barrier (BBB), hindering most drugs to reach the target tissue upon systemic administration. Especially paclitaxel (being effective for the treatment of ovarian, breast, lung and other cancers) is not able to cross the BBB to a notable extent since it is a substrate of the efflux transporter P-glycoprotein. Both, biodegradable microparticles as well as small, cylindrical, glycerol tripalmitate-based implants (which can be injected using standard needles) were prepared with different paclitaxel loadings. The effects of several formulation and processing parameters on the resulting drug release kinetics were investigated in phosphate buffer pH 7.4 as well as in a diethylnicotinamide (DENA)/phosphate buffer mixture. Using DSC, SEM, SEC and optical microscopy deeper insight into the underlying drug release mechanisms could be gained. The presence of DENA in the release medium significantly increased the solubility of paclitaxel, accelerated PLGA degradation, increased the mobility of the polymer and drug molecules and fundamentally altered the geometry of the systems, resulting in increased paclitaxel release rates.


Asunto(s)
Antineoplásicos Fitogénicos/química , Neoplasias Encefálicas/tratamiento farmacológico , Portadores de Fármacos , Implantes de Medicamentos , Paclitaxel/química , Antineoplásicos Fitogénicos/uso terapéutico , Composición de Medicamentos , Cinética , Ácido Láctico/química , Microesferas , Niquetamida/química , Paclitaxel/uso terapéutico , Ácido Poliglicólico/química , Copolímero de Ácido Poliláctico-Ácido Poliglicólico , Polímeros/química , Solubilidad , Tecnología Farmacéutica , Triglicéridos/química
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA